Monday, October 5, 2026

Semiconductor stocks fall 8% as AI chip makers slash Q1 2026 revenue forecasts

Major semiconductor stocks dropped to two-week lows on November 6, 2025, as chip manufacturers issued weak guidance. Microchip Technology forecast Q3 adjusted EPS of 40 cents, Lattice Semiconductor projected Q1 revenue between $158-172 million, and AXT Inc estimated Q4 revenue at $22.5-23.5 million, signaling potential AI infrastructure overcapacity.

Semiconductor stocks fall 8% as AI chip makers slash Q1 2026 revenue forecasts
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Semiconductor stocks declined sharply on November 6, 2025, dragging the S&P 500 to a two-week low as AI chip manufacturers issued conservative revenue forecasts for early 2026.

Microchip Technology projected Q3 adjusted earnings per share of 40 cents. Lattice Semiconductor forecast Q1 revenue between $158 million and $172 million. AXT Inc estimated Q4 revenue at $22.5 million to $23.5 million. The guidance suggests demand cooling across the semiconductor supply chain.

The downturn raises questions about AI infrastructure buildout timelines. Hyperscalers including Google, Microsoft, and Amazon invested over $150 billion in data center infrastructure through 2025. Industry analysts now estimate potential overcapacity in GPU clusters and training infrastructure.

Nvidia, AMD, and Intel shares face pressure through Q1 2026 if the trend continues. AI chip manufacturers expanded production capacity throughout 2024 and 2025 to meet surging demand from large language model developers. Current forecasts indicate that expansion may have outpaced near-term requirements.

The semiconductor industry historically follows cyclical demand patterns, with periods of shortage followed by oversupply. The 2020-2022 chip shortage drove aggressive capacity expansion. Signs emerged in late 2025 that supply finally caught up with demand, potentially overcorrecting.

AI model developers including OpenAI, Anthropic, and Google DeepMind previously cited chip availability as a primary constraint on training timeline and model deployment. Reduced chip scarcity could accelerate LLM development cycles if companies maintain infrastructure spending despite market uncertainty.

Semiconductor market valuations correlate strongly with AI infrastructure spending announcements. Microsoft's January 2025 commitment to $80 billion in data center spending drove chip stock rallies. Recent guidance suggests that momentum may be stalling.

The situation remains fluid through Q1 2026. Chip manufacturers will report earnings in March and April, providing clearer signals about whether the downturn represents temporary demand normalization or a sustained cyclical shift in the AI hardware market.

In this story

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com